• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome.

作者信息

Lenihan Daniel J, Alencar Alvaro J, Yang Deborah, Kurzrock Razelle, Keating Michael J, Duvic Madeleine

机构信息

Department of Cardiology, The University of Texas M.D. Anderson Cancer Center, Houston, USA.

出版信息

Blood. 2004 Aug 1;104(3):655-8. doi: 10.1182/blood-2003-07-2345. Epub 2004 Apr 8.

DOI:10.1182/blood-2003-07-2345
PMID:15073032
Abstract

Alemtuzumab is a monoclonal antibody to CD52 that has activity in T-cell leukemia and lymphoma. This study aims to describe the complications and outcomes of a subset of patients with mycosis fungoides/Sézary syndrome who were treated with alemtuzumab. Four of 8 patients, with no prior history of cardiac problems, developed significant cardiac toxicity (congestive heart failure or arrhythmia) that mostly improved after alemtuzumab discontinuation. The role of this agent in potentially inducing important cardiac side effects is suggested and argues for further investigation.

摘要

相似文献

1
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome.
Blood. 2004 Aug 1;104(3):655-8. doi: 10.1182/blood-2003-07-2345. Epub 2004 Apr 8.
2
Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome.阿仑单抗（抗CD52单克隆抗体）用于晚期蕈样肉芽肿/塞扎里综合征患者的2期研究。
Blood. 2003 Jun 1;101(11):4267-72. doi: 10.1182/blood-2002-09-2802. Epub 2003 Jan 23.
3
No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome.
Blood. 2005 May 15;105(10):4148-9. doi: 10.1182/blood-2004-11-4314.
4
Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab.用阿仑单抗治疗晚期蕈样肉芽肿和塞扎里综合征患者。
Eur J Haematol. 2003 Oct;71(4):250-6. doi: 10.1034/j.1600-0609.2003.00143.x.
5
Cardiac involvement with mycosis fungoides: could this explain alemtuzumab toxicity?蕈样肉芽肿累及心脏：这能解释阿仑单抗的毒性吗？
Leuk Lymphoma. 2008 Oct;49(10):2022-4. doi: 10.1080/10428190801910920.
6
Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center.阿仑单抗治疗复发/难治性红皮病性皮肤 T 细胞淋巴瘤：来自罗伯特·H·卢里综合癌症中心的单机构经验。
Leuk Lymphoma. 2009 Dec;50(12):1969-76. doi: 10.3109/10428190903216770.
7
Mycosis fungoides/Sézary syndrome: a report of three cases treated with Campath-1H as salvage treatment.蕈样肉芽肿/赛塞里综合征：3例采用Campath-1H作为挽救治疗的病例报告。
Med Oncol. 2003;20(4):389-96. doi: 10.1385/MO:20:4:389.
8
Alemtuzumab in Sézary syndrome: efficient but not innocent.阿仑单抗治疗 Sézary 综合征：有效但并非无害。
Eur J Dermatol. 2007 Nov-Dec;17(6):525-9. doi: 10.1684/ejd.2007.0269. Epub 2007 Oct 19.
9
Alemtuzumab treatment for Sézary syndrome: A single-center experience.阿仑单抗治疗 Sézary 综合征：单中心经验
J Dermatolog Treat. 2016;27(2):179-81. doi: 10.3109/09546634.2015.1086479. Epub 2015 Sep 25.
10
Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients.低剂量间歇性阿仑单抗治疗蕈样肉芽肿综合征：14例患者的临床和免疫学发现
Haematologica. 2007 Jun;92(6):784-94. doi: 10.3324/haematol.11127.

引用本文的文献

1
Cardiovascular Disease After Hematopoietic Stem Cell Transplantation in Adults: State-of-the-Art Review.成人造血干细胞移植后的心血管疾病：最新综述
JACC CardioOncol. 2024 Aug 20;6(4):475-495. doi: 10.1016/j.jaccao.2024.06.004. eCollection 2024 Aug.
2
Acute Coronary Syndrome as an Unusual Initial Presentation of T-Prolymphocytic Leukemia: A Case Report and Review of the Literature.急性冠状动脉综合征作为T-原淋巴细胞白血病的一种不寻常初始表现：一例病例报告及文献复习
Case Rep Hematol. 2024 Aug 27;2024:4303614. doi: 10.1155/2024/4303614. eCollection 2024.
3
Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer.
1,3-双四氢呋喃-2-基-5-FU 的合成、表征及作为胰腺癌潜在治疗剂的抗癌活性评价。
BMC Cancer. 2022 Dec 22;22(1):1345. doi: 10.1186/s12885-022-10449-y.
4
Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management.单克隆抗体在复发性多发性硬化症治疗中的应用：重点关注妊娠、疫苗接种和风险管理的概述。
Neurotherapeutics. 2022 Apr;19(3):753-773. doi: 10.1007/s13311-022-01224-9. Epub 2022 Apr 4.
5
Novel targeted therapies of T cell lymphomas.T 细胞淋巴瘤的新型靶向治疗。
J Hematol Oncol. 2020 Dec 31;13(1):176. doi: 10.1186/s13045-020-01006-w.
6
Atypical Mature T-Cell Neoplasms: The Relevance of the Role of Flow Cytometry.非典型成熟T细胞肿瘤：流式细胞术作用的相关性
Onco Targets Ther. 2020 Aug 3;13:7605-7614. doi: 10.2147/OTT.S258512. eCollection 2020.
7
Alemtuzumab induced ST-segment elevation and acute myocardial dysfunction.阿仑单抗诱发ST段抬高和急性心肌功能障碍。
J Cardiol Cases. 2014 Jul 28;10(5):176-179. doi: 10.1016/j.jccase.2014.07.004. eCollection 2014 Nov.
8
Novel Cancer Therapeutics in Geriatrics: What is Unique to the Aging Patient?老年癌症的新型治疗方法：老年患者的独特之处是什么？
Drugs Aging. 2019 Jan;36(1):1-11. doi: 10.1007/s40266-018-0619-2.
9
Anticancer Therapy-Induced Atrial Fibrillation: Electrophysiology and Related Mechanisms.抗癌治疗引起的心房颤动：电生理学及相关机制
Front Pharmacol. 2018 Oct 16;9:1058. doi: 10.3389/fphar.2018.01058. eCollection 2018.
10
Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives.心脏肿瘤学：分子靶向时代与癌症治疗相关的心血管并发症：新概念与新视角
Cureus. 2017 May 18;9(5):e1258. doi: 10.7759/cureus.1258.